Trial Profile

Effects of Empagliflozin in Reducing Oxidative Stress of Diabetic Recipients After Kidney Transplantation

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Insulin
Indications Metabolic disorders; Type 2 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

15 Jul 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2025.
15 Jul 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2024.
27 Jan 2022 Planned End Date changed from 1 Feb 2022 to 1 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com